Prevalencia de sarcopenia y características de los sarcopénicos en pacientes mayores de 80 años ingresados por fractura de cadera

Sánchez-Castellano, C.; Martín‐Aragón, Sagrario; Vaquero-Pinto, Nieves; Bermejo-Bescós, Paloma; Miguel, Ana Merello de; Cruz-Jentoft, Alfonso J.

doi:10.20960/nh.02607

Cited by 5 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Baseline characteristics of the 150 participants are listed in Table , and we previously published these results in detail elsewhere . In brief, mean age was 87.6 ± 4.9 years, and 78.7% were women.…”

Section: Resultsmentioning

confidence: 99%

Biomarkers of sarcopenia in very old patients with hip fracture

Sánchez-Castellano

Martín‐Aragón

Bermejo-Bescós

et al. 2020

J cachexia sarcopenia muscle

Self Cite

View full text Add to dashboard Cite

Background Hip fracture is both a cause and a consequence of sarcopenia. Older persons with sarcopenia have an increased risk of falling, and the prevalence of sarcopenia may be increased in those who suffer a hip fracture. The aim of this study was to explore potential biomarkers (neuromuscular and peripheral pro-inflammatory and oxidative stress markers) that may be associated with sarcopenia in very old persons with hip fracture. Methods We recruited 150 consecutive patients ≥80 years old admitted to an orthogeriatric unit for an osteoporotic hip fracture. Muscle mass was assessed pre-operatively using bioelectrical impedance analysis; Janssen's (J) and Masanés' (M) reference cut-off points were used to define low muscle mass. Muscle strength was assessed with handgrip strength (Jamar's dynamometer). Sarcopenia was defined by having both low muscle mass and strength and using the European Working Group on Sarcopenia in Older People 2 definition of probable sarcopenia (low grip strength). Peripheral markers-pro-inflammatory and oxidative stress parameters-were determined either in the plasma or in the erythrocyte fraction obtained from peripheral whole blood of every patient pre-operatively. Results Mean age was 87.6 ± 4.9 years, and 78.7% were women. The prevalence of sarcopenia was 11.5% with Janssen's, 34.9% with Masanés' cut-offs, and 93.3% with the European Working Group on Sarcopenia in Older People 2 definition of probable sarcopenia. Among the four pro-inflammatory cytokines tested in plasma, only tumour necrosis factor-α was different (lower) in sarcopenic than in non-sarcopenic participants using both muscle mass cut-offs (J 7.9 ± 6.2 vs. 8.3 ± 5.8, M 6.8 ± 4.7 vs. 9.1 ± 6.2). Erythrocyte glutathione system showed a non-significant tendency to lower glutathione levels and glutathione/oxidized glutathione ratios in sarcopenic participants compared with non-sarcopenic subjects. Catalase activity was also lower in sarcopenic participants (J 2904 ± 1429 vs. 3329 ± 1483, M 3037 ± 1430 vs. 3431 ± 1498). No significant differences were found between groups in chymotrypsin-like activity of the 20S proteasome, superoxide dismutase, glutathione peroxidase and butyrylcholinesterase activity, C-terminal agrin fragment, interferon-γ, or interleukin-1β. Conclusions The prevalence of sarcopenia in patients with hip fracture varies according to the definition and the muscle mass reference cut-off points used. We did not find differences in most neuromuscular, pro-inflammatory, or oxidative stress markers, except for lower peripheral tumour necrosis factor-α levels and catalase activity in sarcopenic participants, which may be markers of an early inflammatory reaction that is hampered in sarcopenic patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Biomarkers of sarcopenia in very old patients with hip fracture

Sánchez-Castellano

Martín‐Aragón

Bermejo-Bescós

et al. 2020

J cachexia sarcopenia muscle

Self Cite

View full text Add to dashboard Cite

show abstract

“…For instance, in Spain, Cervera-Días et al identified the highest percentage of sarcopenia among 186 patients hospitalized for hip fracture, 76.9% (mean age 86.2 years) [ 37 ]. On the other hand, in the study of Sánchez-Castellano et al, the sarcopenia prevalence among 150 patients (mean age 87.6 years) was estimated to be between 11.5 and 34.9% according to different equations used to estimate muscle mass (bioimpedance, using two different cut-off points, Janssen and Masanés) [ 10 ]. González-Montalvo et al detected 17.1% sarcopenics among 479 acute hip fracture patients (mean age 85.3 years) [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…The latest projections from the Spanish National Statistics Institute (INE) indicate that in 2050, 31.4% of the population will be aged over 65 years and 11.6% will be octogenarians [ 9 ]. Recent estimates also show that the prevalence of sarcopenia in older hip fracture patients in Spain ranged from 21 to 74% in men and 12 to 68% in women, depending on its definition and diagnosis [ 10 ]. Sarcopenia and hip fracture are considered major public health problems in the geriatric population requiring substantial costs for their management [ 8 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Calf Circumference, a Valuable Tool to Predict Sarcopenia in Older People Hospitalized with Hip Fracture

Borges

Artacho

Jodar-Graus³

et al. 2022

Nutrients

View full text Add to dashboard Cite

Sarcopenia is an important risk factor for hip fracture in older people. Nevertheless, this condition is overlooked in clinical practice. This study aimed to explore the factors associated with sarcopenia among older patients hospitalized for hip fracture, to identify a predictive model of sarcopenia based on variables related to this condition, and to evaluate the performance of screening tools in order to choose the most suitable to be adopted in routine care of older people with hip fracture. A cross-sectional study was undertaken with 90 patients (mean age 83.4 ± 7.2 years), by assessing sociodemographic and clinical characteristics, anthropometric measures, such as body mass index (BMI) and calf circumference (CC), the functional status (Barthel Index), the nutritional status (MNA-SF), and the adherence to the Mediterranean Diet (MEDAS). Diagnosis of sarcopenia was established according to the criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2). The analysis of variables associated with sarcopenia was performed using multivariate logistic regression models. Clusters of sarcopenia were explored with heatmaps and predictive risk models were estimated. Sarcopenia was confirmed in 30% of hip fracture patients. Variables with the strongest association with sarcopenia were BMI (OR = 0.79 [0.68–0.91], p < 0.05) and CC (OR = 0.64 [0.51–0.81], p < 0.01). CC showed a relatively high predictive capacity of sarcopenia (area under the curve: AUC = 0.82). Furthermore, CC could be a valuable tool to predict sarcopenia risk compared with the currently used screening tools, SARC-F and SARC-CalF (AUC, 0.819 vs. 0.734 and 0.576, respectively). More studies are needed to validate these findings in external study populations.

show abstract

“…A cross-sectional study exploring neuromuscular, peripheral pro-inflammatory, and oxidative stress molecules as potential biomarkers associated with sarcopenia in old-aged people with hip fracture only found differences in peripheral TNF-α levels and catalase activity. Probably, TNF-α and catalase are markers of an early inflammatory reaction that is impaired in subjects with sarcopenia [12].…”

Section: Inflammatory Markers In Sarcopeniamentioning

confidence: 99%

Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions

et al. 2021

View full text Add to dashboard Cite

Introduction Sarcopenia is defined by a loss of muscle mass and function associated with mortality, decreased physical performance, falls, and disability. Since chronic inflammation and decreased physical activity are risk factors for developing sarcopenia, it is critical to assess the role of sarcopenia in immune-mediated rheumatic diseases (IMRDs). Moreover, nutritional interventions are emerging as key modifiable and affordable options to improve physical performance in sarcopenia. Objective The aim of this review is to critically summarize current information on the evidence linking nutritional interventions and sarcopenia in IMRDs. Methods The search and selection of articles was performed in Medline, Dimensions.ai, Google Scholar, Cochrane Library, Epistemonikos, and Trip Database. The results were clustered into three areas: sarcopenia and IMRDs, sarcopenia and biological disease-modifying antirheumatic drugs (bDMARDs), and nutritional interventions for sarcopenia. Findings Several cross-sectional studies have shown a higher prevalence of sarcopenia in IMRDs, such as rheumatoid arthritis. Although not fully established, evidence linking sarcopenia and other IMRDs (ankylosing spondylitis and systemic sclerosis) has been also described. For secondary sarcopenia prevention and treatment, bDMARDs’ administration proved efficacy in patients with rheumatoid arthritis. Furthermore, there is growing evidence linking nutrition to the prevention and treatment of sarcopenia. Evidence linking unfavourable results in nutritional risk assessment, insufficient intake of protein, vitamin D, antioxidant nutrients, and long-chain polyunsaturated fatty acids and sarcopenia have been reported. Conclusion Given that sarcopenia and IMRDs have strong links, further research is needed to improve patient care.

show abstract

Prevalencia de sarcopenia y características de los sarcopénicos en pacientes mayores de 80 años ingresados por fractura de cadera

Cited by 5 publications

References 30 publications

Biomarkers of sarcopenia in very old patients with hip fracture

Biomarkers of sarcopenia in very old patients with hip fracture

Calf Circumference, a Valuable Tool to Predict Sarcopenia in Older People Hospitalized with Hip Fracture

Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions

Contact Info

Product

Resources

About